Jay A Grobler
Overview
Explore the profile of Jay A Grobler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1806
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caraco Y, Johnson M, Chiarappa J, Maas B, Stone J, Rizk M, et al.
Clin Trials
. 2025 Mar;
:17407745251313925.
PMID: 40025641
Background: Pre-specified interim analyses allow for more timely evaluation of efficacy or futility, potentially accelerating decision-making on an investigational intervention. In such an analysis, the randomized, double-blind MOVe-OUT trial demonstrated...
2.
Diamond T, Goh S, Ngo W, Rodriguez S, Xu M, Klein D, et al.
Antimicrob Agents Chemother
. 2024 Jun;
68(7):e0033424.
PMID: 38864613
Islatravir (ISL) is a deoxyadenosine analog that inhibits HIV-1 reverse transcription by multiple mechanisms. Lenacapavir (LEN) is a novel capsid inhibitor that inhibits HIV-1 at multiple stages throughout the viral...
3.
Strizki J, Grobler J, Murgolo N, Fridman A, Johnson M, Du J, et al.
Infect Dis Ther
. 2024 Apr;
13(5):1159-1160.
PMID: 38662333
No abstract available.
4.
Arribas J, Bhagani S, Lobo S, Khaertynova I, Mateu L, Fishchuk R, et al.
NEJM Evid
. 2024 Feb;
1(2):EVIDoa2100044.
PMID: 38319178
BACKGROUND: Molnupiravir is an oral prodrug of β-D-N4-hydroxycytidine, active against SARS-CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe-IN, a clinical trial...
5.
Johnson M, Strizki J, Jensen E, Cohen J, Katlama C, Fishchuk R, et al.
Microbiol Spectr
. 2024 Feb;
12(3):e0356323.
PMID: 38299867
Importance: Respiratory viral coinfections are known to occur with coronavirus disease-2019 (COVID-19). In a cohort of non-hospitalized adults with mild-to-moderate COVID-19 treated with molnupiravir versus placebo in the MOVe-OUT trial...
6.
Strizki J, Grobler J, Murgolo N, Fridman A, Johnson M, Du J, et al.
Infect Dis Ther
. 2023 Nov;
12(12):2725-2743.
PMID: 37995070
Introduction: The randomized, placebo-controlled, double-blind MOVe-OUT trial demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for outpatient treatment of mild-to-moderate COVID-19, significantly reducing the...
7.
Johnson M, Strizki J, Brown M, Wan H, Shamsuddin H, Ramgopal M, et al.
Infection
. 2023 Jan;
51(5):1273-1284.
PMID: 36648627
Purpose: Immunocompromised patients have a potentially increased risk for progression to severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis examined outcomes among immunocompromised participants in the MOVe-OUT...
8.
Diamond T, Ngo W, Xu M, Goh S, Rodriguez S, Lai M, et al.
Antimicrob Agents Chemother
. 2022 May;
66(6):e0013322.
PMID: 35546110
Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that inhibits human immunodeficiency virus (HIV) reverse transcription by blocking reverse transcriptase (RT) translocation on the primer:template. ISL is being...
9.
Lai M, Feng M, Xu M, Ngo W, Diamond T, Hwang C, et al.
Antimicrob Agents Chemother
. 2022 May;
66(5):e0222321.
PMID: 35491829
Doravirine (DOR), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for treatment of HIV-1 infection in 2018. In the pivotal phase 3 trials, DRIVE-FORWARD and DRIVE-AHEAD, 7 out of 747...
10.
Jayk Bernal A, Gomes da Silva M, Musungaie D, Kovalchuk E, Gonzalez A, Delos Reyes V, et al.
N Engl J Med
. 2021 Dec;
386(6):509-520.
PMID: 34914868
Background: New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory...